Grupo BMH
Barragán E, Chillón MC, Castelló-Cros R, Marcotegui N, Prieto MI, Hoyos M, Pippa R, Llop M, Cervera J, Rodríguez G, Buño I, Sierra J, González M, Calasanz MJ, Sanz MA, Odero MD. CIP2A overexpression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica (en prensa).


Adema V, Larráyoz MJ, Calasanz MJ, Palomo L, Patiño-García A, Agirre X, Hernández-Rivas JM, Lumbreras E, Buño I, Martinez-Laperche C, Mallo M, García O, Álvarez S, Blazquez B, Cervera J, Luño E, Valiente A, Vallespí MT, Arenillas L, Collado R, Pérez-Oteyza J, Solé F. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations. Br J Haematol (en prensa).


White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajič T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Müller MC, Hochhaus A, Schimmel H, Cross NC, Emons H. A certified plasmid reference material for the standardization of BCR-ABL1 mRNA quantification by real time quantitative PCR. Leukemia 29(2):369-76, 2015.


Bilbao-Sieyro C, Santana G, Moreno M, Torres L, Santana-Lopez G, Rodriguez-Medina C, Perera M, Bellosillo B, de la Iglesia S, Molero T, Gómez-Casares MT. High Resolution Melting Analysis: A Rapid and Accurate Method to Detect CALR Mutations. PLoS One 9:e103511, 2014.


Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 93:2037-43, 2014


Lippert E, Mansier O, Migeon M, Denys B, Nilson A, Rosmond C, Lodé L, Ugo V, Lascaux A, Bellosillo B, Martinez-Lopez J, Naguib D, Gachard N, Maroc N, Hermouet S. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis. Haematologica 99: e098-101, 2014


Caraballo JM, Acosta JC, Cortés MA, Albajar M, Gómez-Casares MT, Batlle-López A, Cuadrado MA, Onaindia A, Bretones G, Llorca J, Piris MA, Colomer D, León J. High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. Oncotarget, 5(13):4694-708, 2014.


Bosch-Vizcaya A, Rodríguez-Romanos R, Nieto JB, De La Cámara R, Brunet S, Vallejo C, Osca G, Martínez-Laperche C, Buño I, Urbano-Ispizúa A, González M, Jiménez-Velasco A, Gallardo D. Effect of mismatching for minor histocompatibility antigen UTA2-1 on clinical outcome after HLA-identical sibling donor allogeneic stem cell transplantation. Bone Marrow Transplant 50(2):298-300, 2014


Salgado RN, Menezes J, Calvente M, Suela J, Acquadro F, Martínez-Laperche C, Flores R, Trujillo M, Alvarez S, Cigudosa JC. Myeloid neoplasms with der(1)t(1;19) may constitute a specific entity characterized by a cytogenetic biomarker and gene mutations involved in DNA methylation. Leuk Lymphoma 55(11):2652-5, 2014.


Martínez-Trillos A, Maffioli M, Colomer D, Alvarez-Larrán A, Pereira A, Angona A, Bellosillo B, Cervantes F. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. Ann Hematol 93(5):797-802, 2014.


Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, Rozman M, Colomer D, Delgado J, Giné E, González-Díaz M, Hernández-Rivas JM, Colado E, Rayón C, Payer AR, Terol MJ, Navarro B, Quesada V, Puente XS, Rozman C, López-Otín C, Campo E, López-Guillermo A, Villamor N. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood 123(24):3790-6, 2014.


Menezes J, Acquadro F, Wiseman M, Gómez-López G, Salgado RN, Talavera-Casañas JG, Buño I, Cervera JV, Montes-Moreno S, Hernández-Rivas JM, Ayala R, Calasanz MJ, Larrayoz MJ, Brichs LF, Gonzalez-Vicent M, Pisano DG, Piris MA, Álvarez S, Cigudosa JC. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 28(4):823-9, 2014.


Guillaumet-Adkins A, Richter J, Odero MD, Sandoval J, Agirre X, Catala A, Esteller M, Prósper F, Calasanz MJ, Buño I, Kwon M, Court F, Siebert R, Monk D. Hypermethylation of the alternative AWT1 promoter in haematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. J Hematol Oncol 7(1):4, 2014.


Osorio S, García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Martínez-Laperche C, Díez-Martín JL, Buño I. Chronic Myeloid Leukemia (CML): Is loss of Major Molecular Response (MMR) actually considered as treatment failure in the 2013 European LeukemiaNet (ELN) Recommendations? [e-Letter], Blood (http://bloodjournal.hematologylibrary.org/content/122/6/872/reply#bloodjournal_el_8602). January 31, 2014.


Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L, Fernández-Rodríguez C, Gómez M, Lombardía L, Angona A, Ancochea A, Senín A, Longarón R, Navarro B, Collado M, Besses C. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89(5):517-23, 2014


Arenillas L, Mallo M, Ramos F, Guinta K, Barragán E, Lumbreras E, Larráyoz MJ, De Paz R, Tormo M, Abáigar M, Pedro C, Cervera J, Such E, José Calasanz M, Díez-Campelo M, Sanz GF, Hernández JM, Luño E, Saumell S, Maciejewski J, Florensa L, Solé F. Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes Cancer 52(12):1167-77, 2013.


López-Jorge CE, Gómez-Casares MT, Jiménez-Velasco A, García-Bello MA, Barrios M, Lopez J, de la Iglesia S, Ramírez T, Sánchez G, Heiniger AI, Molero T. Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. Ann Hematol 91(8):1245-50, 2012. López-Jorge CE, Gómez-Casares MT, Jiménez-Velasco A, García-Bello MA, Barrios M, Lopez J, de la Iglesia S, Ramírez T, Sánchez G, Heiniger AI, Molero T. Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. Ann Hematol 91(8):1245-50, 2012.
Enlace al documento

Kwon M, Martínez-Laperche C, Infante M, Carretero F, Balsalobre P, Serrano D, Gayoso J, Pérez-Corral A, Anguita J, Díez-Martín JL, Buño I. Evaluation of minimal residual disease estimated by real-time quantitative PCR of Wilms’ tumor gene 1 (WT1) transcript expression in adults with acute myeloid leukemia after allogeneic stem cell transplantation. Correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant 18(8):1235-1242, 2012.
Enlace al documento

Fuster O, Barragán E, Bolufer P, Such E, Valencia A, Ibáñez M, Dolz S, de Juan I, Jiménez A, Gómez MT, Buño I, Martínez J, Cervera J, Montesinos P, Moscardó F, Sanz MÁ. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. Ann Hematol 91(1):1-7, 2012.
Enlace al documento

Fuster O, Barragán E, Bolufer P, Cervera J, Larráyoz MJ, Jiménez-Velasco A, Martínez-López J, Valencia A, Moscardó F, Sanz MA. Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. J Mol Diagn 11(5):458-63, 2009.
Enlace al documento

Bolufer P, Colomer D, Gomez MT, Martínez J, Gonzalez SM, Gonzalez M, Nomdedeu J, Bellosillo B, Barragán E, Lo-Coco F, Diverio D, Hermosin L, García-Marco J, De Juan MD, Barros F, Romero R, Sanz MA. Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: multiinstitutional laboratory trial. Clin Chem 50(6):1088-92, 2004.
Enlace al documento

Bolufer P, Lo Coco F, Grimwade D, Barragán E, Diverio D, Cassinat B, Chomienne C, Gonzalez M, Colomer D, Gomez MT, Marugan I, Román J, Delgado MD, García-Marco JA, Bornstein R, Vizmanos JL, Martinez B, Jansen J, Villegas A, de Blas JM, Cabello P, Sanz MA. Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. Haematologica 86(6):570-6, 2001.
Enlace al documento

Bolufer P, Barragán E, Sánz MA, Martín G, Bornstein R, Colomer D, Delgado MD, González M, Marugan I, Román J, Gómez MT, Anguita E, Diverio D, Chomienne C, Briz M. Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemia. Leukemia 12(12):2024-8, 1998.
Enlace al documento